8月 2026
- 首頁
- PANTHERx Rare
8月 2026PANTHERx Rare的市場佔有率分析
PANTHER Power is a children’s book created by our clinical leaders to help young patients understand injectable therapy in a gentle, age‑appropriate way.
PANTHERx Rare(包含公司地區)
查看更多網站流量與參與度資訊- pantherxrare.com
PANTHERx Rare截至 8月 2026 的總收入為 > 1B
PANTHERx Rare 熱門網域產生的總收入
PANTHERx Rare 熱門網域 3 年內的總收入
PANTHERx Rare 熱門網域的總收入
PANTHERx Rare的熱門網域總造訪量
了解PANTHERx Rare市場觸達率與潛在市場影響力。
過去 3 個月的訪問總量
子公司細目
PANTHERx Rare的熱門網域平均造訪時長
分析PANTHERx Rare參與度指標。
過去 3 個月平均造訪時長
子公司細目
PANTHERx Rare的熱門網域平均頁面瀏覽量
了解PANTHERx Rare如何保持使用者的參與度、培養其興趣,並鼓勵他們採取下一步。
過去 3 個月平均頁面瀏覽量
子公司細目
想要取得更深入的流量洞見?
篩選超過 2,030 萬家線上企業。在流量激增、開始或停止使用技術或獲得正面評價時,發現新的潛在客戶。
新聞與訊號來自PANTHERx Rare
透過 Similarweb 銷售訊號提醒,每當目標受眾出現新的機會或威脅時,你就會收到每日更新的已識別購買訊號。
新聞PANTHERx Rare, LLC. signed new client Egetis Therapeutics AB on Sep 28th '26.Egetis has opened its RareLink patient support program and enlisted PANTHERx Rare to support specialty distribution, education and care coordination.
9月 29, 2026閱讀更多
新聞PANTHERx Rare, LLC. signs new client Intercept Pharmaceuticals, Inc..PANTHERx Rare has been selected by Intercept Pharmaceuticals, Inc., a wholly owned subsidiary of Alfasigma S.p.A., as the exclusive U.S. specialty pharmacy partner to distribute LYNAVOY (linerixibat), the first FDA-approved treatment specifically indicated for cholestatic pruritus in adults with primary biliary cholangitis (PBC).
8月 30, 2026閱讀更多
新聞Warburg Pincus was planning to acquire PANTHERx Rare, LLC. on Jul 13th '26.Warburg Pincus announced on July 13 that a Warburg Pincus-led investor group has agreed to acquire a controlling interest in PANTHERx Rare, an independent rare pharmacy in the United States, from Nautic Partners, General Atlantic, and The Vistria Group.
7月 13, 2026閱讀更多
查看所有PANTHERx Rare信號
讓銷售團隊專注於最有希望的機會。透過安排機會的優先順序,並在正確的時間參與,您可將工作最佳化,並完成更多交易。
